Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797249 | 0.90 | MEN1 (0.43) | SLC5A1SLC5A2RORCMEN1KMT2A | |
| SCHEMBL18205764 | 0.84 | MAPT (0.44) | RORCPTGER4RXFP1ALDH1A1BCHE | |
| SCHEMBL16797240 | 0.79 | SLC5A1 (0.41) | SLC5A1SLC5A2RORCMEN1KMT2A | |
| SCHEMBL16797158 | 0.75 | PTGER4 (0.59) | RORCGAAPTGER4ALDH1A1 | |
| SCHEMBL18205763 | 0.74 | RORC (0.43) | RORCRXFP1ALDH1A1 | |
| SCHEMBL16797231 | 0.73 | RORC (0.58) | RORC | |
| SCHEMBL16797233 | 0.73 | MAPT (0.48) | GAAPTGER4RXFP1ALDH1A1 | |
| SCHEMBL16797230 | 0.71 | RORC (0.54) | RORCPTGER4 | |
| SCHEMBL16797222 | 0.71 | MEN1 (0.41) | SLC5A1SLC5A2MEN1KMT2AGAA | |
| SCHEMBL16797163 | 0.70 | CNR1 (0.45) | SLC5A1SLC5A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | RORA, RORB, RORC | SLC5A1 4632/4885SLC5A2 4817/4885RORC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.